Inify Laboratories announces NOK 100m equity raise for UK expansion

Inify Laboratories has announced application periods for a fully guaranteed private placement and a fully guaranteed repair issue, aiming to raise a total of NOK 100 million. The private placement seeks NOK 92 million from existing shareholders holding over 1,000,000 shares, with a minimum subscription of EUR 100,000, running from December 9 to December 16, 2025. This will be followed by an NOK 8 million repair issue for other existing shareholders.

Both share issues are priced at NOK 3.50 per share, with net proceeds dedicated to ensuring financial stability and supporting larger-than-expected investments for establishing operations in the UK. The repair issue application period is scheduled from approximately January 12 to January 26, 2026. Settlement for both issues is expected by March 25, 2026, with new shares delivered by March 30, 2026.

SB1 Markets AS is acting as financial advisor, and Schjødt law firm as legal counsel. The company, which specializes in histopathology diagnostics for prostate cancer and gastroenterology, is headquartered in Solna, Sweden, with laboratories in Sweden and the UK.